149 Medical
149 Medical is dedicated to improving outcomes for premature infants through innovative, life-changing technology. Their primary focus is on reducing morbidity and mortality by providing continuous, real-time monitoring of cerebral blood flow to detect and mitigate risks such as ventricular hemorrhage. Their flagship device, NIRDS1, is a non-invasive intracranial blood flow sensor validated in over 1,000 children, currently in clinical evaluation, and licensed exclusively from Massachusetts General Hospital. The company's mission is to shift the standard of care from traditional, less effective methods to advanced, early detection technologies, ultimately decreasing disabilities and improving long-term health outcomes for the smallest and most vulnerable patients.
Industries
Nr. of Employees
small (1-50)
149 Medical
Products
Continuous non‑invasive cerebral blood flow monitor (clinical prototype)
A clinical‑stage, non‑invasive optical monitoring system designed to provide continuous real‑time measurements of cerebral blood flow in premature infants to give clinicians an early warning of flow fluctuations associated with intraventricular hemorrhage risk.
Continuous non‑invasive cerebral blood flow monitor (clinical prototype)
A clinical‑stage, non‑invasive optical monitoring system designed to provide continuous real‑time measurements of cerebral blood flow in premature infants to give clinicians an early warning of flow fluctuations associated with intraventricular hemorrhage risk.
Expertise Areas
- Neurophotonics and optical brain monitoring
- Neonatal clinical monitoring and NICU study conduct
- Medical device design and commercialization
- Clinical validation and comparative physiological testing
Key Technologies
- Diffuse correlation spectroscopy (DCS)
- Near‑infrared spectroscopy (NIRS) principles
- Laser speckle / speckle contrast optical sensing
- Coherent light optical probe hardware